UNITED STATES SECURITIES AND EXCHANGE COMMISSION April 24, 2020

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Vanda Pharmaceuticals, Inc.

File No. 1-34186 - CF#35036

Vanda Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on March 13, 2015.

Based on representations by Vanda Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time period specified:

Exhibit 10.56	through May 15, 2023
Exhibit 10.58	through May 15, 2023
Exhibit 10.59	through May 15, 2023
Exhibit 10.60	through May 15, 2023
Exhibit 10.62	through May 15, 2023

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Vanessa A. Countryman Secretary